Trastuzumab, a humanised monoclonal antibody targeting HER2, was the first clinically approved targeted therapy for the treatment of HER2+ve breast cancer and is now used routinely as the first-line therapy [4]. This evidence concerns the gene ERBB2 and breast cancer.